MetLife Investment Management’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $515K | Buy |
45,218
+3,113
| +7% | +$35.5K | ﹤0.01% | 1665 |
|
|
2025
Q1 | $500K | Sell |
42,105
-434
| -1% | -$5.16K | ﹤0.01% | 1730 |
|
|
2024
Q4 | $801K | Buy |
42,539
+7,300
| +21% | +$138K | ﹤0.01% | 1534 |
|
|
2024
Q3 | $792K | Buy |
35,239
+168
| +0.5% | +$3.78K | ﹤0.01% | 1527 |
|
|
2024
Q2 | $732K | Buy |
35,071
+11,783
| +51% | +$246K | ﹤0.01% | 1516 |
|
|
2024
Q1 | $342K | Hold |
23,288
| – | – | ﹤0.01% | 1896 |
|
|
2023
Q4 | $240K | Hold |
23,288
| – | – | ﹤0.01% | 2133 |
|
|
2023
Q3 | $183K | Hold |
23,288
| – | – | ﹤0.01% | 2270 |
|
|
2023
Q2 | $233K | Hold |
23,288
| – | – | ﹤0.01% | 2182 |
|
|
2023
Q1 | $207K | Hold |
23,288
| – | – | ﹤0.01% | 2201 |
|
|
2022
Q4 | $256K | Hold |
23,288
| – | – | ﹤0.01% | 2097 |
|
|
2022
Q3 | $303K | Hold |
23,288
| – | – | ﹤0.01% | 2013 |
|
|
2022
Q2 | $295K | Buy |
23,288
+4,618
| +25% | +$58.5K | ﹤0.01% | 2036 |
|
|
2022
Q1 | $262K | Buy |
18,670
+6,891
| +59% | +$96.5K | ﹤0.01% | 2186 |
|
|
2021
Q4 | $341K | Hold |
11,779
| – | – | ﹤0.01% | 1725 |
|
|
2021
Q3 | $353K | Hold |
11,779
| – | – | ﹤0.01% | 1733 |
|
|
2021
Q2 | $312K | Buy |
11,779
+2,269
| +24% | +$60.2K | ﹤0.01% | 1861 |
|
|
2021
Q1 | $296K | Buy |
9,510
+4,421
| +87% | +$137K | ﹤0.01% | 1820 |
|
|
2020
Q4 | $167K | Hold |
5,089
| – | – | ﹤0.01% | 2077 |
|
|
2020
Q3 | $178K | Buy |
+5,089
| New | +$178K | ﹤0.01% | 1929 |
|